144.12
3.69%
+5.13
After Hours:
144.00
-0.12
-0.08%
BeiGene Ltd ADR stock is currently priced at $144.12, with a 24-hour trading volume of 215.69K.
It has seen a +3.69% increased in the last 24 hours and a -5.20% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $138.6 pivot point. If it approaches the $146.2 resistance level, significant changes may occur.
Previous Close:
$138.99
Open:
$143.45
24h Volume:
215.69K
Market Cap:
$15.06B
Revenue:
$2.46B
Net Income/Loss:
$-881.71M
P/E Ratio:
-8.6311
EPS:
-16.6978
Net Cash Flow:
$-1.75B
1W Performance:
+9.30%
1M Performance:
-5.20%
6M Performance:
-16.67%
1Y Performance:
-44.01%
BeiGene Ltd ADR Stock (BGNE) Company Profile
Name
BeiGene Ltd ADR
Sector
Industry
Phone
345-949-4123
Address
94 Solaris Avenue, Camana Bay, George Town
BeiGene Ltd ADR Stock (BGNE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-06-24 | Resumed | JP Morgan | Overweight |
Sep-12-23 | Initiated | Macquarie | Outperform |
Aug-17-23 | Initiated | Jefferies | Buy |
Jul-17-23 | Initiated | Citigroup | Buy |
Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
Jan-12-23 | Initiated | Daiwa Securities | Buy |
Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Aug-09-22 | Resumed | JP Morgan | Overweight |
Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Feb-07-22 | Initiated | Deutsche Bank | Buy |
Oct-12-21 | Initiated | Bernstein | Outperform |
Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
Mar-08-21 | Initiated | China Renaissance | Buy |
Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
Jul-10-20 | Downgrade | CLSA | Buy → Outperform |
Mar-13-20 | Upgrade | Macquarie | Underperform → Neutral |
Feb-18-20 | Resumed | Goldman | Buy |
Jan-17-20 | Upgrade | CLSA | Outperform → Buy |
Jan-17-20 | Resumed | Morgan Stanley | Overweight |
Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
Dec-16-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
Nov-19-19 | Downgrade | UBS | Buy → Neutral |
Nov-13-19 | Downgrade | CLSA | Buy → Outperform |
Nov-04-19 | Reiterated | Maxim Group | Buy |
Jun-04-19 | Initiated | Bernstein | Outperform |
May-10-19 | Upgrade | CLSA | Outperform → Buy |
Mar-15-19 | Initiated | BofA/Merrill | Buy |
Jan-04-19 | Downgrade | CLSA | Buy → Outperform |
Nov-21-18 | Initiated | JP Morgan | Overweight |
Sep-25-18 | Initiated | Leerink Partners | Outperform |
May-17-18 | Reiterated | Maxim Group | Buy |
View All
BeiGene Ltd ADR Stock (BGNE) Latest News
Evaluating BeiGene: Insights From 6 Financial Analysts
Benzinga
4 Analysts Assess BeiGene: What You Need To Know
Benzinga
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Benzinga
Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Seeking Alpha
BeiGene Ltd ADR Stock (BGNE) Financials Data
BeiGene Ltd ADR (BGNE) Revenue 2024
BGNE reported a revenue (TTM) of $2.46 billion for the quarter ending December 31, 2023, a +73.65% rise year-over-year.
BeiGene Ltd ADR (BGNE) Net Income 2024
BGNE net income (TTM) was -$881.71 million for the quarter ending December 31, 2023, a +56.00% increase year-over-year.
BeiGene Ltd ADR (BGNE) Cash Flow 2024
BGNE recorded a free cash flow (TTM) of -$1.75 billion for the quarter ending December 31, 2023, a +10.79% increase year-over-year.
BeiGene Ltd ADR (BGNE) Earnings per Share 2024
BGNE earnings per share (TTM) was -$8.58 for the quarter ending December 31, 2023, a +55.70% growth year-over-year.
BeiGene Ltd ADR Stock (BGNE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
OYLER JOHN | Chief Executive Officer |
Apr 11 '24 |
Sale |
146.73 |
12,084 |
1,773,085 |
0 |
OYLER JOHN | Chief Executive Officer |
Apr 10 '24 |
Sale |
148.89 |
26,716 |
3,977,861 |
12,084 |
OYLER JOHN | Chief Executive Officer |
Apr 09 '24 |
Sale |
153.94 |
11,200 |
1,724,078 |
38,800 |
OYLER JOHN | Chief Executive Officer |
Mar 13 '24 |
Sale |
177.56 |
12,332 |
2,189,648 |
0 |
OYLER JOHN | Chief Executive Officer |
Mar 12 '24 |
Sale |
164.02 |
37,668 |
6,178,369 |
12,332 |
Wang Julia Aijun | Chief Financial Officer |
Feb 29 '24 |
Sale |
167.08 |
397 |
66,331 |
0 |
Lee Chan Henry | SVP, General Counsel |
Jul 31 '23 |
Sale |
216.26 |
791 |
171,059 |
0 |
Wang Julia Aijun | Chief Financial Officer |
Jul 03 '23 |
Sale |
179.55 |
472 |
84,747 |
0 |
Wu Xiaobin | President, COO & GM China |
Jun 26 '23 |
Sale |
182.37 |
1,495 |
272,636 |
0 |
Wang Lai | Global Head of R&D |
Jun 26 '23 |
Sale |
181.92 |
1,108 |
201,567 |
0 |
About BeiGene Ltd ADR
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has strategic collaborations with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317; Merck KGaA to research and develop on BGB-290 and BGB-283; and MEI Pharma, Inc. to evaluate the safety and efficacy of ME-401, an investigational PI3K delta inhibitor in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Cap:
|
Volume (24h):